<code id='04AC7EAF53'></code><style id='04AC7EAF53'></style>
    • <acronym id='04AC7EAF53'></acronym>
      <center id='04AC7EAF53'><center id='04AC7EAF53'><tfoot id='04AC7EAF53'></tfoot></center><abbr id='04AC7EAF53'><dir id='04AC7EAF53'><tfoot id='04AC7EAF53'></tfoot><noframes id='04AC7EAF53'>

    • <optgroup id='04AC7EAF53'><strike id='04AC7EAF53'><sup id='04AC7EAF53'></sup></strike><code id='04AC7EAF53'></code></optgroup>
        1. <b id='04AC7EAF53'><label id='04AC7EAF53'><select id='04AC7EAF53'><dt id='04AC7EAF53'><span id='04AC7EAF53'></span></dt></select></label></b><u id='04AC7EAF53'></u>
          <i id='04AC7EAF53'><strike id='04AC7EAF53'><tt id='04AC7EAF53'><pre id='04AC7EAF53'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:knowledge    Page View:6522
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In